EFM
KZR

E Fund Management’s Kezar Life Sciences KZR Stock Holding History

E Fund Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,415
Closed -$44K – 328
2023
Q1 		$44K Sell
1,415
-412
-23% -$23.8K ﹤0.01% 332
2022
Q4 		$129K Buy
1,827
+145
+9% +$10.8K 0.01% 318
2022
Q3 		$145K Buy
+1,682
New +$163K 0.01% 318

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

E Fund Management's KZR Position: Q2 2023 in Review

E Fund Management sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 1,415 shares — an estimated $44K sold.

E Fund Management first reported a position in KZR in Q3 2022 and held it in 3 quarters. The position peaked at $145K in Q3 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • E Fund Management reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • E Fund Management sold 1,415 Kezar Life Sciences shares in Q2 2023, an estimated $44K.
  • E Fund Management first reported a position in Kezar Life Sciences in Q3 2022 and held it in 3 quarters.
  • E Fund Management's Kezar Life Sciences position peaked at $145K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.